DNA vaccine VGX-3100 with electroporation induces regression of cervical intraepithelial neoplasia 2/3 and clears HPV infection with robust T cell responses: results of a randomized, double-blind, placebo-controlled Phase II trial. (6th November 2014) - Humeau, Laurent; Trimble, Cornelia; Morrow, Matthew; Shen, Xuefei; Dallas, Michael; Weiner, David; Boyer, Jean; Yan, Jian; Kraynyak, Kimberly; Sylvester, Albert; Giffear, Mary; Marcozzi-Pierce, Kathy; et al.